AstraZeneca inks kidney therapy deal worth up to $1.77B with China’s CSPC
Seeking Alpha ·
AstraZeneca ( AZN ) has reached a partnership worth up to $1.77B with CSPC Pharmaceutical Group ( CSPCY ) to develop and commercialize treatments for kidney diseases, Reuters reported on Thursday, based on a regulatory filing from the Chinese company.
DYAX Investor Sentiment
Bullish (Long) 34% · Bearish (Short) 66%
401 participants
Related News
- This Artificial Intelligence (AI) Chip Giant Is a Profit-Making Machine. Its Latest Move Could Supercharge the Stock
- Tesla rolls out robotaxi service in Miami
- UPAY Inc. Announces Appointment of Wynand Jordaan as Non-Executive Director
- Meta AI agents not advancing as quickly as planned, Zuckerberg tells staff: report
- Ripple Is Bringing Agentic AI Payments to the XRP Blockchain. Is This a Game Changer for XRP?
- He Predicted the Dot-com Bubble Burst. Now He's Saying SpaceX Could be a Fresh Warning Sign.